In This Section      
 

Search Results

Title:
Immune Evaluation Study of Sipuleucel-T in African American and non-African American Men with Castrate Resistant Prostate Cancer (Karmanos Cancer Institute protocol # 2013-108)
Protocol Number:
J1409
Phase:
NULL
Physician:
Channing Paller
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Sibley Memorial Hospital
Purpose:
This research is being done to collect samples of blood from men diagnosed with Advanced Prostate Cancer and are receiving sipuleucel-T as a part of their treatment.
Eligibility:
Men diagnosed with Advanced Prostate Cancer and are receiving sipuleucel-T as a part of their treatment may join.
Treatment:
The primary objective of the study is to estimate the mean level of each of the immune parameters from blood samples collected from African American (AA) and Non-African American ( non AA) prostate cancer patients receiving sipuleucel-T treatment. The secondary objective is to estimate the rate of each of several types of immune response separately in AA and non AA prostate cancer patients receiving sipuleucel-T treatment.
Population:
Adult
Last Update
12/14/2019 05:03 AM